The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer
Open accessAbstract
IMPORTANCE: Adult survivors of childhood cancer are known to be at risk for treatment-related adverse health outcomes. A large population of survivors has not been evaluated using a comprehensive systematic clinical assessment to determine the prevalence of chronic health conditions. OBJECTIVE: To determine the prevalence of adverse health outcomes and the proportion associated with treatment-related exposures in a large cohort of adult survivors of childhood cancer. DESIGN, SETTING, AND PARTICIPANTS: Presence of health outcomes was ascertained using systematic exposure-based medical assessments among 1713 adult (median age, 32 [range, 18-60] years) survivors of childhood cancer (median time from diagnosis, 25 [range, 10-47] years) enrolled in the St Jude Lifetime Cohort Study since October 1, 2007, and undergoing follow-up through October 31, 2012. MAIN OUTCOMES AND MEASURES: Age-specific cumulative prevalence of adverse outcomes by organ system. RESULTS: Using clinical criteria, the crude prevalence of adverse health outcomes was highest for pulmonary (abnormal pulmonary function, 65.2% [95% CI, 60.4%-69.8%]), auditory (hearing loss, 62.1% [95% CI, 55.8%-68.2%]), endocrine or reproductive (any endocrine condition, such as hypothalamic-pituitary axis disorders and male germ cell dysfunction, 62.0% [95% CI, 59.5%-64.6%]), cardiac (any cardiac condition, such as heart valve disorders, 56.4% [95% CI, 53.5%-59.2%]), and neurocognitive (neurocognitive impairment, 48.0% [95% CI, 44.9%-51.0%]) function, whereas abnormalities involving hepatic (liver dysfunction, 13.0% [95% CI, 10.8%-15.3%]), skeletal (osteoporosis, 9.6% [95% CI, 8.0%-11.5%]), renal (kidney dysfunction, 5.0% [95% CI, 4.0%-6.3%]), and hematopoietic (abnormal blood cell counts, 3.0% [95% CI, 2.1%-3.9%]) function were less common. Among survivors at risk for adverse outcomes following specific cancer treatment modalities, the estimated cumulative prevalence at age 50 years was 21.6% (95% CI, 19.3%-23.9%) for cardiomyopathy, 83.5% (95% CI, 80.2%-86.8%) for heart valve disorder, 81.3% (95% CI, 77.6%-85.0%) for pulmonary dysfunction, 76.8% (95% CI, 73.6%-80.0%) for pituitary dysfunction, 86.5% (95% CI, 82.3%-90.7%) for hearing loss, 31.9% (95% CI, 28.0%-35.8%) for primary ovarian failure, 31.1% (95% CI, 27.3%-34.9%) for Leydig cell failure, and 40.9% (95% CI, 32.0%-49.8%) for breast cancer. At age 45 years, the estimated cumulative prevalence of any chronic health condition was 95.5% (95% CI, 94.8%-98.6%) and 80.5% (95% CI, 73.0%-86.6%) for a serious/disabling or life-threatening chronic condition. CONCLUSIONS AND RELEVANCE: Among adult survivors of childhood cancer, the prevalence of adverse health outcomes was high, and a systematic risk-based medical assessment identified a substantial number of previously undiagnosed problems that are more prevalent in an older population. These findings underscore the importance of ongoing health monitoring for adults who survive childhood cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rückinger, S., von Kries, R., & Toschke, A. M. (2009) · BMC Medical Research Methodology · doi:10.1186/1471-2288-9-7 · Cited by 162
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338
Bhakta, N., Liu, Q., Ness, K. K., Baassiri, M., Eissa, H., Yeo, F., Chemaitilly, W., Ehrhardt, M. J., Bass, J., Bishop, M. W., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31610-0 · Cited by 862
Self-citationArmenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70409-7 · Cited by 570
Self-citationSklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01175 · Cited by 224
Self-citationFrailty in childhood cancer survivors
Ness, K. K., Armstrong, G. T., Kundu, M., Wilson, C. L., Tchkonia, T., & Kirkland, J. L. (2015) · Cancer · doi:10.1002/cncr.29211 · Cited by 188
Self-citationClinical strategies and animal models for developing senolytic agents
Kirkland, J. L., & Tchkonia, T. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2014.10.012 · Cited by 168
Psychosocial Late Effects in Pediatric Cancer Survivors: A Report From the Children's Oncology Group
Bitsko, M. J., Cohen, D., Dillon, R., Harvey, J., Krull, K., & Klosky, J. L. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25773 · Cited by 148
Self-citationHodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Age-Dependent Changes in Health Status in the Childhood Cancer Survivor Cohort
Hudson, M. M., Oeffinger, K. C., Jones, K., Brinkman, T. M., Krull, K. R., Mulrooney, D. A., Mertens, A., Castellino, S. M., Casillas, J., Gurney, J. G., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4863 · Cited by 113
Self-citationAriffin, H., Azanan, M. S., Abd Ghafar, S. S., Oh, L., Lau, K. H., Thirunavakarasu, T., Sedan, A., Ibrahim, K., Chan, A., Chin, T. F., et al. (2017) · Cancer · doi:10.1002/cncr.30857 · Cited by 99
Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia
Edelmann, M. N., Krull, K. R., Liu, W., Glass, J. O., Ji, Q., Ogg, R. J., Sabin, N. D., Srivastava, D. K., Robison, L. L., Hudson, M. M., et al. (2014) · Brain · doi:10.1093/brain/awu230 · Cited by 99
Self-citationExercise intolerance, mortality, and organ system impairment in adult survivors of childhood cancer
Ness, K. K., Plana, J. C., Joshi, V. M., Luepker, R. V., Durand, J. B., Green, D. M., Partin, R. E., Santucci, A. K., Howell, R. M., Srivastava, D. K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01661 · Cited by 96
Self-citationSex-Specific Cardiovascular Risks of Cancer and Its Therapies
Wilcox, N. S., Rotz, S. J., Mullen, M., Song, E. J., Ky Hamilton, B., Moslehi, J., Armenian, S. H., Wu, J. C., Rhee, J.-W., & Ky, B. (2022) · Circulation Research · doi:10.1161/circresaha.121.319901 · Cited by 86
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
Reimagining care for adolescent and young adult cancer programs: Moving with the times
Gupta, A. A., Papadakos, J. K., Jones, J. M., Amin, L., Chang, E. K., Korenblum, C., Mina, D. S., McCabe, L., Mitchell, L., & Giuliani, M. E. (2016) · Cancer · doi:10.1002/cncr.29834 · Cited by 76
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma
Edelmann, M. N., Daryani, V. M., Bishop, M. W., Liu, W., Brinkman, T. M., Stewart, C. F., Mulrooney, D. A., Kimberg, C., Ness, K. K., Cheung, Y. T., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4398 · Cited by 55
Self-citationFeijen, E. A. M., Teepen, J. C., van Dulmen‐den Broeder, E., van den Heuvel‐Eibrink, M. M., van der Heiden‐van der Loo, M., van der Pal, H. J. H., de Vries, A. C. H., Louwerens, M., Bresters, D., Versluys, B., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30212 · Cited by 41
Sexual dysfunction in young adult survivors of childhood cancer - a population-based study
Hovén, E., Fagerkvist, K., Jahnukainen, K., Ljungman, L., Lähteenmäki, P. M., Axelsson, O., Lampic, C., & Wettergren, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.014 · Cited by 37
Neurocognitive and behavioral outcomes of Chinese survivors of childhood lymphoblastic leukemia
Peng, L., Yang, L. S., Yam, P., Lam, C. S., Chan, A. S.-Y., Li, C. K., & Cheung, Y. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.655669 · Cited by 29
Psychosexual development and sexual functioning in young adult survivors of childhood cancer
Lehmann, V., Gerhardt, C. A., Baust, K., Kaatsch, P., Hagedoorn, M., & Tuinman, M. A. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.07.014 · Cited by 17
Streefkerk, N., Teepen, J. C., Feijen, E. A. M., Jóźwiak, K., van der Pal, H. J. H., Ronckers, C. M., De Vries, A. C. H., Van der Heiden‐van Der Loo, M., Hollema, N., van den Berg, M., et al. (2024) · Cancer · doi:10.1002/cncr.35148 · Cited by 15
Maas, A., Maurice‐Stam, H., Feijen, E. A. M. (., Teepen, J. C., van der Aa‐van Delden, A. M., Streefkerk, N., van Dulmen‐den Broeder, E., Tissing, W. J. E., Loonen, J. J., van der Pal, H. J. H., et al. (2024) · Psycho-Oncology · doi:10.1002/pon.9313 · Cited by 8
Maas, A., Maurice-Stam, H., Feijen, L. E. A. M., Teepen, J. C., van der Aa-van Delden, A. M., Streefkerk, N., van Dulmen-den Broeder, E., Tissing, W. J. E., Loonen, J. J., van der Pal, H. J. H., et al. (2025) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01617-z · Cited by 7
Metadata
- Authors
- Hudson, M. M., Ness, K. K., Gurney, J. G., Mulrooney, D. A., Chemaitilly, W., Krull, K. R., Green, D. M., Armstrong, G. T., Nottage, K. A., Jones, K. E., Sklar, C. A., Srivastava, D. K., & Robison, L. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-12
- Volume
- 309
- Issue
- 22
- Pages
- 2371
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2014432477
- Cited by
- 1,248
- References
- 1
- FWCI
- 78.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.